Improvement of anthracycline chemotherapy by enhancement of apoptotic responses and tumour targeted activation. Improved outcomes for anthracycline anticancer chemotherapy is of clear benefit to the nation. Tumour-localised treatment is expected to lead to improved responses, reduced side-effects and improved quality of life while rational selection of drug combinations is expected to enable treatment of tumours that were previously resistant to anthracyclines. With an aging population in Austra ....Improvement of anthracycline chemotherapy by enhancement of apoptotic responses and tumour targeted activation. Improved outcomes for anthracycline anticancer chemotherapy is of clear benefit to the nation. Tumour-localised treatment is expected to lead to improved responses, reduced side-effects and improved quality of life while rational selection of drug combinations is expected to enable treatment of tumours that were previously resistant to anthracyclines. With an aging population in Australia the incidence of cancer is predicted to rise dramatically - improved treatment outcomes and better use of chemotherapeutics will be of obvious national benefit. The development of new tumour-targeted agents is the subject of joint Intellectual Property between Australia and the USA, offering potential economic benefit. Read moreRead less
Tumour localisation and enhancement of anthracycline anticancer activity. The anthracyclines are one of the most widely used anticancer agents today. If the cytotoxicity of these agents can be localised to tumour cells, or their activity improved, then this will result in improved response rates, less side-effects and an improved quality of life for many patients for whom anthracycline treatment is an important part of their therapy. This will result in enormous national/community benefit to an ....Tumour localisation and enhancement of anthracycline anticancer activity. The anthracyclines are one of the most widely used anticancer agents today. If the cytotoxicity of these agents can be localised to tumour cells, or their activity improved, then this will result in improved response rates, less side-effects and an improved quality of life for many patients for whom anthracycline treatment is an important part of their therapy. This will result in enormous national/community benefit to an aging Australian population that is becoming increasingly more prone to cancer. Read moreRead less
Anticancer drug development: Enhancing the anticancer activity of mitoxantrone. Many cancer sufferers may benefit from this work if we are able to develop more active derivatives of mitoxantrone, or develop procedures to inhibit the repair of DNA lesions induced by mitoxantrone. This may result in therapies with improved response, reduced drug dosage and/or reduced side-effects. Because this work may result in one or more patents, and possibly commercialisation with Australian (and overseas) pha ....Anticancer drug development: Enhancing the anticancer activity of mitoxantrone. Many cancer sufferers may benefit from this work if we are able to develop more active derivatives of mitoxantrone, or develop procedures to inhibit the repair of DNA lesions induced by mitoxantrone. This may result in therapies with improved response, reduced drug dosage and/or reduced side-effects. Because this work may result in one or more patents, and possibly commercialisation with Australian (and overseas) pharmaceutical companies, there are potential commercial benefits to Australia. The "discovery" aspect of this work may also identify other cellular responses to mitoxantrone (ie specific genes which are re-expressed) and this may also reveal new targets to further enhance the activity of this drug.Read moreRead less
Molecular basis for the synergistic potentiation of anthracycline anticancer agents by formaldehyde-releasing prodrugs. AIMS: The overall aim is to develop a full understanding of the molecular basis for the synergistic activation of Adriamycin (and other anthracycline anticancer agents) by formaldehyde-releasing prodrugs such as AN-9.
SIGNIFICANCE: Because Adriamycin is currently one of the most widely used anticancer agents, and this activity has the potential to be dramatically enhanced by t ....Molecular basis for the synergistic potentiation of anthracycline anticancer agents by formaldehyde-releasing prodrugs. AIMS: The overall aim is to develop a full understanding of the molecular basis for the synergistic activation of Adriamycin (and other anthracycline anticancer agents) by formaldehyde-releasing prodrugs such as AN-9.
SIGNIFICANCE: Because Adriamycin is currently one of the most widely used anticancer agents, and this activity has the potential to be dramatically enhanced by the concurrent use of formaldehyde-releasing prodrugs, a biochemical understanding of these processes will provide the basis to exploit this synergy to provide improved treatment outcomes (eg, lower drug doses,reduced side-effects, improved activity against drug-resistanct tumours etc).
EXPECTED OUTCOMES: The long-term outcome of this project is commercialisation to develop products for clinical use based on this synergy (eg, drug/prodrug combinations) and ultimately the development of tumour-directed therapy to yield a tumour-localised anticancer response.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE160100900
Funder
Australian Research Council
Funding Amount
$366,000.00
Summary
Smart aptamer-guided nanoexosome as a novel biotechnology platform. This project aims to develop guided novel nanomaterials as a new biotechnological platform for in vivo targeted delivery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) for gene editing. By systematically engineering the surface properties of natural nanovesicles known as exosomes, a novel nanotechnology platform should be established. The guided nano biotechnological platform should not only enable targete ....Smart aptamer-guided nanoexosome as a novel biotechnology platform. This project aims to develop guided novel nanomaterials as a new biotechnological platform for in vivo targeted delivery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) for gene editing. By systematically engineering the surface properties of natural nanovesicles known as exosomes, a novel nanotechnology platform should be established. The guided nano biotechnological platform should not only enable targeted in vivo precision gene editing via CRISPR but also specific delivery of gene editing machinery across the blood brain barrier for better exploration of fundamental biology of the brain.Read moreRead less
Understanding how RNA editing regulates RNA fate. This project aims to address how RNA editing mediated by ADAR1 alters the interactions of targeted RNA with the innate immune sensing system. ADAR1 editing converts adenosine to inosine within double stranded RNA. It is known that this is key to prevent activation of the innate immune sensor MDA5 by endogenous RNA. However, we do not understand why edited RNA is tolerated and unedited RNA is not. This project will generate new knowledge regarding ....Understanding how RNA editing regulates RNA fate. This project aims to address how RNA editing mediated by ADAR1 alters the interactions of targeted RNA with the innate immune sensing system. ADAR1 editing converts adenosine to inosine within double stranded RNA. It is known that this is key to prevent activation of the innate immune sensor MDA5 by endogenous RNA. However, we do not understand why edited RNA is tolerated and unedited RNA is not. This project will generate new knowledge regarding the effect of editing on how endogenous RNA is perceived by the innate immune system.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE170100525
Funder
Australian Research Council
Funding Amount
$372,000.00
Summary
Mucus control: Applying concepts from bacteriophage-mucus interactions. This project aims to examine how mucus-adherent bacteriophage interact with bacteria in mucus as a mechanism to manipulate microbiomes. Bacterial infections at mucosal surfaces in animals are a serious global health threat. Traditionally antibiotics have been used to curb mucosal infections, but antibiotic resistance means new therapies are urgently needed. Bacteriophage – viruses that infect bacteria – can kill bacteria and ....Mucus control: Applying concepts from bacteriophage-mucus interactions. This project aims to examine how mucus-adherent bacteriophage interact with bacteria in mucus as a mechanism to manipulate microbiomes. Bacterial infections at mucosal surfaces in animals are a serious global health threat. Traditionally antibiotics have been used to curb mucosal infections, but antibiotic resistance means new therapies are urgently needed. Bacteriophage – viruses that infect bacteria – can kill bacteria and might provide a layer of antimicrobial immunity in animal mucus. The anticipated outcomes are resolving how bacteriophage control bacteria within mucus, and applying concepts to bioengineer mucosal microbiomes.Read moreRead less
New insulins for the improved management of diabetes. The prevalence of diabetes has increased dramatically over the past few decades and now this condition is widely considered the world’s fastest growing disease. New insulins with improved pharmacological and storage properties are desperately needed, and this project will work on chemical synthesis enabling designer insulins to be prepared for improved management of diabetes.
Peptide-based Star Polymers for Improved Biointeraction and Targeted Anticancer Therapies. The aim of this project is to develop peptide-based star polymer nanocarriers for targeted drug delivery to cancer stem cells which integrate aptamer targeting technology and biointeraction studies with blood plasma fluid. The significance of this research is it pioneers the development of a drug delivery system that minimises plasma opsonization through understanding polymer-plasma interactions, which in ....Peptide-based Star Polymers for Improved Biointeraction and Targeted Anticancer Therapies. The aim of this project is to develop peptide-based star polymer nanocarriers for targeted drug delivery to cancer stem cells which integrate aptamer targeting technology and biointeraction studies with blood plasma fluid. The significance of this research is it pioneers the development of a drug delivery system that minimises plasma opsonization through understanding polymer-plasma interactions, which in turn increases tumour specificity and cell internalisation through incorporation of targeting aptamers and triggered drug release. This project will use rational design, advanced macromolecular engineering and an interdisciplinary collaboration to generate next-generation polymer therapeutics for drug delivery.Read moreRead less
The first integrated multimodal assay for the ultrasensitive detection of dengue contamination of blood. This project will develop the first screening test to check for dengue contamination of blood donations in Australia. This will help ensure safe, continued supply from blood donors, particularly in Queensland where dengue is on the rise.